Login to Your Account



Takeda and India’s Biological E plan to jointly develop low-cost vaccines

By David Ho
Staff Writer

Monday, July 17, 2017

HONG KONG – Japan’s Takeda Pharmaceutical Co. Ltd. and India’s Biological E Ltd. are collaborating to develop and deliver affordable combination vaccines. Under two licensing agreements, Takeda will transfer its measles and acellular pertussis vaccine technologies to Biological E, which will commercialize them in other markets.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription